中文版
Company
|
Technology
|
Product
|
Research
|
Business Development
|
Investor
Contact
Technology
Research
iAPA
TM
Technology
iVac-006 cancer vaccine
iVac-008 vaccine adjuvant
iVac-009 AIDS vaccine
Dendritic cell-based tumor vaccines…More>>
SOCS-1… antitumor immunity…More>>
New approaches to vaccine adjuvant…More>>
An alternative and effective HIV vaccine…More>>
Silencing of SOCS-1 enhances antigen presentation…More>>
Knocking the SOCS1 off DC…More>>
News
ImmunoVac, Inc. Announces Its Platform Technology for the Development of More Effective Tumor Vaccines as Published in Nature Medicine
Identification of "biological brake" could improve cancer vaccines
ImmunoVac, Inc. Announces An Exclusive Worldwide License Agreement with Baylor College of Medicine for A Novel Immunotherapy Technology
HIV Vaccine Takes Different Tack To Boost Immune Response
SOCS1 Silencing Could Help Enhance Vaccines against HIV
SOCS1 Silencing Dramatically Increases the Anti-cancer Efficacy of Dendritic Cell Vaccines
Navigation
Company
Technology
Product
Research
Business Development
Investor
Contact
News & Events
May, 2007 By Baylor College of Medicine
January, 2006 By Science Daily
January, 2006 By Medical Research News
More...
Related Links
Morningside Group
Baylor College of Medicine
网站建设
网站建设
网站建设
CopyRight ©
2007 ImmunoVac Inc All rights reserved.
Registrtion number：321321321
ImmunoVac, Inc. Announces Its Platform Technology for the Development of More Effective Tumor Vaccines as Published in Nature Medicine